TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 0.200nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Affinity DataKi: 0.200nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Affinity DataKi: 0.280nMAssay Description:Inhibition of human recombinant NEP by fluorescence assayMore data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 0.316nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Affinity DataKi: 0.316nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Affinity DataKi: 0.501nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 0.501nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 0.631nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Affinity DataKi: 0.631nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Affinity DataKi: 0.700nMAssay Description:In vivo inhibitory potency against neutral endopeptidase by displacement of [3H]-HACBOGly binding in mouse kidneyMore data for this Ligand-Target Pair
Affinity DataKi: 0.700nMAssay Description:Inhibition of human recombinant NEP using Suc-Ala-Ala-Phe-AMC as substrate after 30 mins by fluorimetryMore data for this Ligand-Target Pair
Affinity DataKi: 0.700nMAssay Description:In vivo inhibitory potency against neutral endopeptidase by displacement of [3H]-HACBOGly binding in mouse kidneyMore data for this Ligand-Target Pair
Affinity DataKi: 0.800nMAssay Description:Inhibition of human recombinant NEP by fluorescence assayMore data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 1nMAssay Description:The assays were performed in 384-well white opaque plates at 37? C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair